Aptorum Group Limited (APM )

Currency in USD Disclaimer
$1.61 -$0.36 (-18.27%)
Closed 07/18/2025
$1.53
$2.02
$0.46
$7.49

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol APM
  • Company Aptorum Group Limited
  • Price $1.61
  • Changes Percentage -18.27
  • Change -0.36
  • Day Low $1.53
  • Day High $2.02
  • Year High $7.49
  • Year Low $0.46
  • Market Cap $11,501,449
  • Price Avg 50 EMA (D) $1.03
  • Price Avg 200 EMA (D) $1.1
  • Exchange NASDAQ
  • Volume 1,286,626
  • Average Volume 3,305,543
  • Open $1.97
  • Previous Close $1.97
  • EPS -0.78
  • PE -2.06
  • Earnings Announcement 2025-07-30 04:00:00
  • Shares Outstanding $7,143,757

Company brief: APTORUM GROUP LIMITED (APM )

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

APM Corporation News

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

July 16, 2025 at 12:38 pm ET

globenewswire.com -- NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing un...

Income Statement